Health
Animal data supports efficacy of baricitinib vs SARS-COV-2 – News-Medical.Net
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 202…
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inflammatory Responses in COVID-19
Severe COVID-19 is associated with high fever, non-…
-
Noosa News20 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General14 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business22 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
Business24 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today